WebApr 13, 2024 · Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor types. Biomarkers are biological indicators used to select patients for a systemic anticancer treatment, but ... WebMay 20, 2024 · The recent phase II clinical trial, KEYNOTE-158, demonstrated the clinical benefit of therapy with pembrolizumab among patients with previously treated unresectable or metastatic, high MSI, DNA MMR deficient, non-colorectal cancer ; with only four patients with SCLC enrolled in this study, further investigation will be required.
MSI-H固形癌 KEYNOTE-158 臨床試験サマリ OncoTribune
WebSep 1, 2024 · KEYNOTE-158 used a cutoff of ≥10 Mut/Mb using the FoundationOne CDx panel to define TMB-H. This cutoff appeared to identify patients in the dataset with a likelihood of responding to pembrolizumab therapy; however, occasional responses were also reported in the non–TMB-H group in this trial. WebPubMed Central (PMC) low pressure tankless water heater
Pembrolizumab for Persistent, Recurrent, or Metastatic …
WebApr 3, 2024 · KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from … WebApr 6, 2024 · Merck has the industry's largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. ... In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with MSI-H or dMMR cancer were similar to those occurring in … WebApr 6, 2024 · KEYNOTE-158 is an ongoing global, multicohort, single-arm, open-label phase 2 study that evaluates pembrolizumab monotherapy in patients with one of the following less frequently occurring advanced solid tumour types: anal squamous cell carcinoma (cohort A), biliary adenocarcinoma (except ampulla of Vater cancers; cohort B), neuroendocrine … low pressure tanning bed